机器学习整合临床与遗传标志物预测类风湿关节炎抗TNF药物反应
本研究利用DREAM挑战赛数据,构建高斯过程回归模型预测1,892例RA患者抗TNF治疗后DAS28变化并分类应答者,在680例独立数据集中验证。模型交叉验证预测ΔDAS28相关系数0.405、正确分类78%患者,独立测试Pearson相关系数0.393,为DREAM挑战赛最佳模型。
要点
- 高斯过程回归模型可预测RA患者抗TNF治疗后ΔDAS28并分类应答。
- 交叉验证正确分类78%患者,独立测试预测ΔDAS28相关系数0.393。
- 遗传SNP标志物在临床模型基础上贡献较小。
核心结论
- 整合临床与遗传信息的高斯过程回归模型在预测抗TNF药物反应方面显示潜力,主要基于临床特征。
研究设计与样本
- 利用DREAM类风湿关节炎应答者挑战赛数据,构建高斯过程回归模型预测ΔDAS28并分类应答者。
- 模型在1,892例RA患者中开发与交叉验证,在680例独立数据集中评估。
主要发现
- 交叉验证中预测ΔDAS28的相关系数为0.405,正确分类78%患者的应答状态。
- 独立测试中预测ΔDAS28的Pearson相关系数为0.393。
- 高斯过程回归有效重映射特征空间并识别对抗TNF治疗反应不佳的亚群。
- 遗传SNP标志物加入临床模型后预测贡献较小。
- 该模型为DREAM挑战赛中表现最佳的模型。
临床怎么用
- 模型主要基于临床特征并辅以遗传信息,有望辅助临床治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Accurate prediction of treatment responses in rheumatoid arthritis (RA) patients can provide valuable information on effective drug selection. Anti-tumor necrosis factor (anti-TNF) drugs are an important second-line treatment after methotrexate, the classic first-line treatment for RA. However, patient heterogeneity hinders identification of predictive biomarkers and accurate modeling of anti-TNF drug responses. This study was undertaken to investigate the usefulness of machine learning to assist in developing predictive models for treatment response. METHODS: Using data on patient demographics, baseline disease assessment, treatment, and single-nucleotide polymorphism (SNP) array from the Dialogue on Reverse Engineering Assessment and Methods (DREAM): Rheumatoid Arthritis Responder Challenge, we created a Gaussian process regression model to predict changes in the Disease Activity Score in 28 joints (DAS28) for the patients and to classify them into either the responder or the nonresponder group. This model was developed and cross-validated using data from 1,892 RA patients. It was evaluated using an independent data set from 680 patients. We examined the effectiveness of the similarity modeling and the contribution of individual features. RESULTS: In the cross-validation tests, our method predicted changes in DAS28 (ΔDAS28), with a correlation coefficient of 0.405. It correctly classified responses from 78% of patients. In the independent test, this method achieved a Pearson's correlation coefficient of 0.393 in predicting ΔDAS28. Gaussian process regression effectively remapped the feature space and identified subpopulations that do not respond well to anti-TNF treatments. Genetic SNP biomarkers showed small contributions in the prediction when added to the clinical models. This was the best-performing model in the DREAM Challenge. CONCLUSION: The model described here shows promise in guiding treatment decisions in clinical practice, based primarily on clinical profiles with additional genetic information.
引用
- Guan Y, Zhang H, Quang D, et al. Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. Arthritis Rheumatol. 2019. PMID: 31342661. doi:10.1002/art.41056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。